Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Penpulimab in combination with chemotherapy for metastatic nasopharyngeal...

Dr Aditya Shreenivas - CIty of Hope, Duarte, USA

Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results ( Dr Aditya Shreenivas - CIty of Hope, Duarte, USA )

Addition of pembrolizumab to standard care shows promising results in advanced...

Dr Ravindra Uppaluri - Dana-Farber Brigham Cancer Center, Boston, USA

Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer ( Dr Ravindra Uppaluri - Dana-Farber Brigham Cancer Center, Boston, USA )

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma

Dr Milad Ibrahim - NYU Langone Health, New York, USA

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma ( Dr Milad Ibrahim - NYU Langone Health, New York, USA )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in...

Dr Giulia Pasello - University of Padova, Padua, Italy

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC ( Dr Giulia Pasello - University of Padova, Padua, Italy )

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer ( Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA )

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive...

Dr Sacha Rothschild - University of Basel, Basel, Switzerland

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC ( Dr Sacha Rothschild - University of Basel, Basel, Switzerland )

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced...

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

Treatment with BAY 2927088 led to durable responses in patients previously...

Prof Nicolas Girard - Institut Curie, Paris, France

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus...

Prof Nicolas Girard - Institut Curie, Paris, France

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )

Consolidation durvalumab after cCRT shows decreased disease progression in LS...

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC ( Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )

More from ecancer